Jeffrey Eisele - 23 Jan 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Development Officer
Signature
/s/ David Watson, attorney-in-fact for Jeffrey Eisele
Issuer symbol
APLS
Transactions as of
23 Jan 2023
Transactions value $
-$231,027
Form type
4
Filing time
25 Jan 2023, 15:14:36 UTC
Previous filing
24 Jan 2023
Next filing
30 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale -$231K -4.48K -8.58% $51.58 47.7K 23 Jan 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale originated from established 10b5-1 trading plan.